Related Experiment Video
Updated: Aug 13, 2025
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Synergistic Pro-Apoptotic Effect of a Cyclic RGD Peptide-Conjugated Magnetic Mesoporous Therapeutic Nanosystem on
Xuanping Zhao1,2, Chuan Liu1,2, Zichao Wang1,2
1College of Bioengineering, Henan University of Technology, Zhengzhou 450001, China.
Abstract:
Numerous nanocarriers have been developed to deliver drugs for the treatment of hepatocellular carcinoma. However, the lack of specific targeting ability, the low administration efficiency, and insufficient absorption by hepatocellular carcinoma cells, severely limits the therapeutic effect of the current drugs. Therefore, it is still of great clinical significance to develop highly efficient therapies with few side effects for the treatment of hepatocellular carcinoma. Herein, we developed a highly effective nanocarrier, cyclic RGD peptide-conjugated magnetic mesoporous nanoparticles (RGDSPIO@MSN NPs), to deliver the chemotherapeutic drug doxorubicin (DOX) to human hepatocellular carcinoma HepG2 cells, and further explored their synergistic apoptosis-promoting effects. The results showed that the prepared RGDSPIO@MSN NPs had good stability, biosafety and drug-loading capacity, and significantly improved the absorption of DOX by HepG2 cells, and that the RGDSPIO@MSN@DOX NPs could synergistically promote the apoptosis of HepG2 cells. Thus, this cyclic RGD peptide-modified magnetic mesoporous silicon therapeutic nanosystem can be regarded as a potentially effective strategy for the targeted treatment of hepatocellular carcinoma.
Insights
New RGD-SPIO@MSN nanoparticles effectively deliver doxorubicin to liver cancer cells. This targeted drug delivery enhances cancer cell absorption and promotes synergistic apoptosis, offering a promising hepatocellular carcinoma treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Hepatocellular carcinoma (HCC) treatment faces challenges with current nanocarriers due to poor targeting, low efficiency, and insufficient cellular uptake.
- Developing targeted, efficient therapies with minimal side effects is crucial for improving HCC treatment outcomes.
Purpose of the Study:
- To develop and evaluate a novel nanocarrier, cyclic RGD peptide-conjugated magnetic mesoporous nanoparticles (RGD-SPIO@MSN NPs), for targeted delivery of doxorubicin (DOX) to HCC cells.
- To investigate the synergistic apoptosis-promoting effects of DOX-loaded RGD-SPIO@MSN NPs in human HCC HepG2 cells.
Main Methods:
- Synthesis and characterization of RGD-SPIO@MSN NPs.
- Drug loading of doxorubicin (DOX) onto the nanoparticles.
- Evaluation of nanoparticle stability, biosafety, and drug-loading capacity.
- Assessment of DOX absorption by HepG2 cells using the prepared nanocarriers.
- Investigation of the synergistic apoptosis-promoting effects of RGD-SPIO@MSN@DOX NPs on HepG2 cells.
Main Results:
- The RGD-SPIO@MSN NPs demonstrated good stability, biosafety, and drug-loading capacity.
- The nanocarrier significantly enhanced the absorption of DOX by HepG2 cells.
- RGD-SPIO@MSN@DOX NPs exhibited synergistic apoptosis-promoting effects on HepG2 cells.
Conclusions:
- The cyclic RGD peptide-modified magnetic mesoporous silicon nanosystem shows potential as an effective strategy for targeted hepatocellular carcinoma treatment.
- This targeted nanocarrier system improves drug delivery efficiency and enhances therapeutic outcomes for HCC.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017